Starling Oncology Raises FY26 Guidance on Positive Cash Flow Shift

Key Facts

1Starling Oncology raised its FY26 guidance, projecting 31% revenue growth and a 41% increase in gross profit.

2The company expects positive free cash flow of $10M and EBITDA between $2M and $7M.

Starling Oncology raised its FY26 guidance, projecting 31% revenue growth and a 41% increase in gross profit. Seeking Alpha reported that the company expects to achieve positive free cash flow of $10M, with EBITDA estimated between $2M and $7M.

The upward revision is driven by scalable delegation contracts and oncology managed care services, which are fueling higher fees and pharmacy growth. STLN closed at $6.51 on September 29, 2026, having traded between a day high of $6.73 and a low of $6.34.